|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Trop-2 staining of archived tumor specimens, clearance of IMMU-132 and its constituents (ie, immunoglobulin G [IgG], SN-38 [a camptothecin, the active component of irinotecan], and glucuronidated SN-38 [SN-38G]), antibody responses, and uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) levels were determined.
|
28558150 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Here we report DNA sequencing, cDNA cloning and mutational analyses of four deleterious mutations (Q118X, 632delA, Q207X and S170X) in M1S1 (formerly TROP2 and GA733-1), encoding a gastrointestinal tumour-associated antigen.
|
10192395 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Trophoblast cell surface antigen 2 (TROP2) or tumor-associated calcium signal transducer 2 (TACSTD2) is a 36-kDa type I transmembrane glycoprotein and exerts dual functions as an oncogene and tumor suppressor in cancer cells.
|
26626643 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The CYCLIN D1-TROP2 mRNA was expressed by a large fraction of the human gastrointestinal, ovarian, and endometrial tumors analyzed.
|
18829570 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Upregulation of Trop-2 was shown to quantitatively stimulate tumour growth, as proportional to expression levels in vivo, and tumour cell growth was abrogated by somatic knockdown of Trop-2 expression.
|
22349828 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TROP2 is known as a calcium signal transducer and is highly expressed in several types of tumors.
|
16707602 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Lentiviral downregulation of endogenous Trop-2 abolished tumor response to AKT blockade, indicating Trop-2 as a mandatory activator of AKT.
|
27022065 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Trop2 overexpression is associated with decreased patient survival as well as increased tumor aggressiveness and metastasis.
|
19683559 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
By flow cytometry, both normal and tumor CR cells expressed basal, luminal, and stem cell markers, with the majority of the normal and tumor CR cells expressing prostate basal cell markers, CD44 and Trop2, as well as luminal marker, CD13, suggesting a transit-amplifying phenotype.
|
28009986 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study aims to investigate the tumor suppressive effects of TROP-2 in cervical cancer cells and to explain the underlying mechanisms.
|
30429055 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Importantly, DDP treatment exhibited a strong antitumor activity in the mice with Trop-2 knockdown tumors, but only a marginal effect in the control group.
|
24025415 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo, Trop2-IgG exerted critical tumor inhibitory effects in OC xenografts.
|
30879767 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings show that upregulation of a wild-type Trop-2 has a key controlling role in human cancer growth, and that tumour development is quantitatively driven by Trop-2 expression levels.
|
22562244 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, the subgroup analysis revealed that the associations between TROP2 overexpression and the outcome endpoints (OS or DFS) were significant in in patients with female genital system neoplasms, as well in gastrointestine neoplasms.
|
27645103 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Co-treatment with anti-ErbB3 and anti-Trop2 antibodies is synergistic and produces a greater anti-tumor response than either antibody alone.
|
29305574 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Incubation with IL-2 further increased the level of cytotoxicity against Trop-2-positive tumors.
|
21889762 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Transfection of short hairpin RNA (shRNA) targeting TROP2 (sh‑TROP2) reduced cell proliferation, migration and invasion of OSCC cell lines, whereas overexpression of TROP2 increased proliferation, migration and invasion. sh‑TROP2 transfection in OSCC cell lines inhibited tumor growth in OSCC mouse models.
|
31638186 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In primary HNSCC, detection of ErbB3 activation was limited to Trop2 negative tumors.
|
25238142 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of Trop2 has been associated with increased tumor aggressiveness, metastasis and decreased patient survival, but the signaling mechanisms mediated by Trop2 are still unknown.
|
20858281 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Trop2+/AREG+ protein coexpression were associated with Tumor Node Metastasis (TNM) stage (χ<sup>2</sup> = 50.345, P < 0.001), tumor size (χ<sup>2</sup> = 40.349, P < 0.001), lymph node metastases (χ<sup>2</sup> = 26.481, P < 0.001), and distant metastases (χ<sup>2</sup> = 8.387, P = 0.039).
|
28256068 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The human trophoblast cell surface antigen 2 (Trop2) belongs to the tumor-associated calcium signal transducer gene family.
|
29901071 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, Trop‑2‑CD40L VLP immunization increased the survival rate of Lewis tumor‑bearing mice more significantly when compared with Trop‑2 only VLPs.
|
29568866 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor tissues showed markedly increased Trop-2 positivity compared with NEC (P = 0.001).
|
21892093 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Further studies are needed to identify biomarkers that indicate how TROP2 signaling affects tumor growth and whether targeting TROP2 would be beneficial to the patient.
|
30002602 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overwhelming evidence has demonstrated that the aberrant expression of the human trophoblast cell-surface antigen (TROP2) was associated with tumor aggressiveness and poor prognosis in a variety of human cancers, however the roles of TROP2 in cervical cancer have not been investigated.
|
24086649 |
2013 |